Introduction
Obsessive Compulsive Disorder (OCD) is a complex mental health condition categorized by repeated thoughts, known as obsessions, and repetitive conduct or actions (compulsions) that impede normal operations. As per Sharma et al (2021), OCD was first acknowledged as a separate condition and documented in the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) in the 1980s. Sharma et al. (2021) estimate OCD’s prevalence at approximately 2% of the world’s adult population.
The fact that many people exhibiting the condition’s signs do not report it or seek medical care implies that exact figures on the disorder’s prevalence are unavailable—the various versions of the DSM feature progressive diagnostic standards and procedures for OCD. The DSM-III categorized OCD as an anxiety-related syndrome, while the DSM-III-R moved the illness to the isolated class titled ‘obsessive-compulsive and related disorders’ (Bhattacharya et al., 2023). This classification was retained in the DSM-IV and DSM-IV-TR, which further included hoarding condition as a linked sickness. The DSM-5 is the latest edition and moves OCD back to the anxiety illnesses classification.
OCD’s diagnostic standards also feature several revisions over the past few days. The DSM-III and DSM-III-R emphasized compulsive thoughts and neurotic conduct as the principal symptoms for the illness’s determination (Fabiano & Haslam, 2020). The DSM-IV and DSM-IV-TR contained revised criteria that comprise the impairment and distress triggered by OCD as part of the signs. The DSM-5 contains further reviewed indicative principles that comprise individuals’ levels of awareness regarding their OCD condition (Rasmussen & Parnas, 2022).
Generally, the various DSM editions reflect advances in the analytical criteria for OCD. The development reflects an increased understanding of the illness and the potential for more advanced, precise diagnostic measures. Trends in OCD’s evidence-based diagnostic procedures also reveal the growing appreciation of the association between the condition and other mental illnesses. OCD’s precise triggers and causal mechanisms are still under study, with the DSM measures being modernized and advanced to offer a better understanding of the complex ailment.
DSM-5-TR Criteria
OCD provides stubborn, undesirable thoughts, known as obsessions, and repetitive performances or compulsions that significantly inhibit day-to-day functioning and trigger agony as the primary features of OCD. Therapists look for these signs to diagnose patients with the condition. These indicators must occur for at least an hour a day and lead to a significant deficiency in occupational, social, and other essential capacities for normal functioning (DSM-5, 2021, p. 239). Generalized anxiety disorder (GAD) is one potential diagnosis to consider in OCD’s differential diagnosis. However, GAD is only an interconnected condition that distinctively differs from OCD through its characteristic extreme anxiety and nervousness (Singh et al., 2023).
On the other hand, OCD is depicted by definite invasive thinking tendencies and tiresome deeds connected to weird moods (DSM-5, 2021, p. 270). Persons with OCD usually identify that their fascinations and compulsions are irrational and extreme (Singh et al., 2023). This aspect contrasts them with individuals experiencing GAD, who frequently do not recognize or lack control over their worry (DSM-5, 2021, p. 271). Thus, OCD and GAD differ significantly despite exhibiting almost similar signs and diagnoses.
The body dysmorphic disorder (BDD) is another differential diagnosis to consider in the case of OCD. BDD is identifiable through observing cases of extreme and unnecessary worry concerning supposed mistakes in one’s bodily appearance (DSM-5, 2021, p. 240). Persons with OCD equally fight with negative body image perspectives and exhibit obsessive behaviors regarding their image. People with BDD symptoms mainly depict anxiety-related signs due to perceived defects, while OCD patients concentrate on intrusive thinking and the necessity to accomplish specific performances to lessen fretfulness (DSM-5, 2021, p. 240).
As well, depression is a significant differential diagnosis for OCD disorder. The two disorders implicate destructive judgments and sensations, with the main discrepancy being that OCD results from anxiety and fear, whereas depression involves obstinate sadness, worthlessness, and hopelessness (DSM-5, 2021, p. 185). Moreover, individuals with OCD symptoms may feel relieved after executing a repetitive or habitual behavior, which is not the case for persons suffering from depression (DSM-5, 2021, p. 185). Accordingly, BDD and depression are mental conditions closely related to OCD, with the two former conditions’ unique symptoms distinguishing them from the latter.
Lastly, attention-deficit/hyperactivity disorder (ADHD) is also considered in the differential diagnosis of OCD. The two conditions relate to difficulties controlling impulses. Equally, OCD and ADHD patients suffer restlessness and distractibility symptoms that make them related (DSM-5 2021, p. 60). A therapist can thus confuse the two because they share several signs.
However, OCD’s compulsive behaviors’ typical drivers are fear and anxiety, whereas restlessness and impulsivity in ADHD are themselves absolute indicators (DSM-5, 2021, p. 60). The existence of these many differential diagnoses implies notable overlap in behaviors and symptoms related to various mental disorders. Nonetheless, OCD exhibits distinctive measures and elements that distinguish it from other linked disorders, including BDD, GAD, ADHD, and depression.
It is critical that clinicians carefully and systematically evaluate and select the best diagnoses to provide the most suitable care for patients. DSM provides medics with evidence-based information to help them make these distinctions. The document undergoes continuous review and revision to capture new knowledge on various health issues. Accordingly, ongoing research on illnesses provides the basis for the review processes.
First-Line, Second-Line, and Third-Line Therapies
Mental health conditions feature several treatment procedures that therapists can employ to cure patients. Treatment approaches are often named according to their effectiveness and side effects, leading to first-, second-, or third-line treatment choices. The National Institute for Health and Care Excellence (NICE) recommends the use of selective serotonin reuptake inhibitors (SSRIs) as the first-line method for treating OCD among adult patients. The method works by boosting serotonin levels in the brain, which helps reduce obsessive thoughts and compulsive behaviors, as noted by Nezgovorova et al. (2022).
The second Second-line OCD treatment involves a combination of an SSRI and a tricyclic antidepressant (TCA) like clomipramine. This blend is significantly active for persons not responding adequately to the first-line care involving SSRI alone. The third-line treatment for OCD involves different antipsychotic medicines, including olanzapine or risperidone.
These treatments are frequently combined with TCA OR SSRI drugs for patients failing to respond to first and second-line therapies. The second-line medication level can also include the combination of an SSRI with an antipsychotic prescription for severe cases. Fluoxetine, sertraline, paroxetine, and fluvoxamine are examples of approved medicines on the market used to manage the condition.
Adding clomipramine to SSRIs therapy constitutes another alternative for the third-line treatment, as per the DSM’s guidelines. Clomipramine is a powerful antidepressant that is tricyclic, applied less often to OCD care because of its higher risk of severe side effects (Xu et al., 2021). The first-line medicine is what medics should try first when presented with an OCD case. The therapists review various signs to rule out other related diagnoses before settling on a treatment plan. First-line care usually involves less severe incidents or patients reporting them for the first time. The approach is less harmful to the body because it uses simple yet effective evidence-based care.
The second-line treatment involves changes in SSRIs, as recommended, and therapists applying them carefully. The professionals closely monitor patients’ responses to determine which drug works for patients requiring this kind of treatment. The last line of treatment, the third-line, is for OCD cases that do not stabilize after using several dissimilar SSRI medicines. This approach is less prescribed due to its adoption of the potentially dangerous tetracyclic drug, Clomipramine.
Thus, NICE recommends treatment for all types of OCS, aiming to ensure safe and comprehensive management of illness. Fineberg et al. (2020) is a meta-analysis study supporting SSRIs’ use as first-line and second-line treatments for OCD management. The scholars show that SSRIs cause more effects than dummy or placebo in decreasing OCD indications, with fluoxetine, fluvoxamine, and sertraline causing the greatest impacts. The work thus reiterates the importance of combining psychological therapies and medication treatment to manage OCD effectively.
First and Second-Line Therapeutic Modality Recommendations
OCD’s first-line therapeutic modality approvals mainly include selective serotonin reuptake inhibitors (SSRIs) like sertraline, paroxetine, or fluoxetine. Fineberg et al. (2020) describe this first-line approach as the most operational management for the condition. The scholars claim that roughly60% of persons displaying OCD symptoms realize notable development under this therapy (Fineberg et al., 2020). This medication increases serotonin levels in the brain, which aids in controlling compulsive behaviors and obsessive thoughts among patients. Interventions like tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs), and antipsychotics constitute second-line OCD therapeutic procedures.
The second level of care, which includes combined therapies, works effectively among individuals who give minimal response to SSRIs alone. The last line of treatments also features a combined approach, including SSRI and TCA medications. Kayser (2020) describes SNRIs as more effective than placebo in treating the condition.
The research further reports that taking SNRIs causes better outcomes with lower cases of adverse events compared to tricyclic antidepressants’ usage, which is often prescribed for third-line care. Also, Kayser (2020) supports the application of antipsychotics in treating OCD. The study reveals second-generation antipsychotics, including quetiapine and risperidone, as effective medicines in lessening OCD symptoms.
Future Research
OCD’s persistence as a mental condition affecting people globally triggers the desire to find working solutions. The aspect indicates a significant knowledge gap regarding the disorder. Research on the issue has the potential to promote deeper understanding and advance the identification and management of the illness. Kashyap and Abramovitch (2021) identify the need for further investigation into OCD’s risk factors, the impact of different treatment methods, underlying causes, and the establishment of tailored interventions as critical future research areas. Linde and Varga (2022) also propose topics such as the role of definite ecological and genetic influences in causing OCD and the assessment of the usefulness of various treatment methods as key future explorations in the field.
Castle et al. (2023) direct scholars to focus on comprehending the long-term outcomes of treatment for OCD patients, with emphasis on documenting re-emergence rates across diverse therapies. Lastly, Wilson et al. (2023) report the significance of exploring comorbid conditions’ connections with OCD symptoms, mainly depression and anxiety, to determine the most appropriate therapy for persons with these compound conditions. Thus, investing in future research on OCD will progress understanding of the condition and augment diagnostic precision and therapy results.
Implications for Future Practice
Conditions affecting people keep changing, requiring medics to acquire new skills to remain effective constantly. Ljungbeck et al. (2021) reiterate the need for psychiatric mental health nursing practitioners (PMHNPs) to remain informed on discoveries in the discipline to offer the best care to patients exhibiting psychiatric mental health issues. The present course perfectly imparts this understanding and provides several fundamental themes that every therapist must adopt in their practice. For example, this training creates awareness of the essence of personalized treatment procedures.
A major concept covered in this class is the need to plan treatment among mentally ill clients. This element highlights the danger of applying a single-answer-fit-all scheme to sick people. It also reiterates the prominence of systematic and in-depth assessments and ongoing care, which tend to define the most effective management strategy for individual patients. The course equips learners to take the time to understand clients’ specific preferences and needs fully, and to adapt treatment plans to their unique traits and needs. That way, the experience I gain in the course prepares me to provide patient-specific treatment through consumer-focused care plans.
The course emphasizes the significance of adopting a holistic slant when taking care of individuals experiencing mental illnesses. For example, the information shows the need for a nurse or therapist to provide care to a person to check other issues related to the condition under management. The professional is required to address the physical, social, and emotional requirements of the sick person. Doing this helps the therapist understand vital underlying conditions that inhibit cure. The strategy facilitates healing by promoting functional commitment and cooperation between the medic and the patient (Bhagat et al., 2023).
The course similarly provides cooperation with a multidisciplinary group as a necessary holistic care measure. Bhagat et al. (2023) say that modern societies feature numerous agencies targeting to solve almost all related issues. However, working in silos affects care providers, as they tend to focus solely on therapy provision. Accordingly, I propose to avoid this issue by collaborating with relevant bodies in my work as a PMHNP. The present training helps me devise appropriate ways to realize this goal by highlighting the importance of collaborating with support systems and families in making treatment decisions.
The course also describes the importance of remaining culturally competent as a medical practitioner. Making medics culturally considerate helps deliver culturally competent care to individuals with mental syndromes (O’Brien et al., 2021). A therapist must understand the social and cultural influences shaping the client’s perspective on mental well-being.
Acknowledging that some groups stigmatize people with mental challenges helps in developing the correct plans to handle the matter effectively. This course presents several ways for mental health professionals to remain culturally sensitive. Evaluating one’s own assumptions and biases regularly is one such covered tactic. The strategy helps medics question and challenge the mindsets of various ethnic groups to provide unbiased care.
Getting education on various cultures is another way of becoming culturally competent, as per the course. Lastly, the training underscores the need to involve clients in the care organization and design to ensure the consideration and protection of their unique cultural values and beliefs. Equally, the course equips learners with the skills to apply pharmacokinetics in the medical sector for people with mental illness. I have already applied this information from the course in my present work to handle patients.
Conclusion
In conclusion, OCD is a multifaceted mental health condition typified by insistent and irrepressible thinking and conduct that challenge people’s daily living. Diagnosing this illness encompasses an all-inclusive evaluation that considers the individual’s symptoms, comorbid conditions, and medical history. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) provides criteria commonly applied in the investigative procedure. The condition’s treatment characteristically includes an amalgamation of psychotherapy and medication, with self-help procedures often adopted. OCD’s first-line treatment includes selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, paroxetine, and sertraline.
The second-line cure comprises the combination of SSRIs with a tricyclic antidepressant (TCA), such as clomipramine. Lastly, the third-line care for OCD comprises assorted antipsychotic medications like risperidone and olanzapine. Thus, the availability of various evidence-based approaches to managing OCD demonstrates the health sector’s commitment to holistic health care. Medics handling patients with this kind of psychological complication have a proven and systematic way to progressively apply the different lines of care until the illness is controlled. Accordingly, the present course provides therapists with invaluable information on the management and treatment of various conditions, enabling them to offer quality care.
References
Bhattacharya, S., Goicoechea, C., Heshmati, S., Carpenter, J. K., & Hofmann, S. G. (2023). Efficacy of cognitive behavioral therapy for anxiety-related disorders: A meta-analysis of recent literature. Current Psychiatry Reports, 25(1), 19-30.
Castle, D., Feusner, J., Laposa, J. M., Richter, P. M., Hossain, R., Lusicic, A., & Drummond, L. M. (2023). Psychotherapies and digital interventions for OCD in adults: What do we know, what do we need still to explore? Comprehensive Psychiatry, 120(15), 23-57.
Diagnostic and Statistical Manual of Mental Disorders (DSM-5). (2021).
Fabiano, F., & Haslam, N. (2020). Diagnostic inflation in the DSM: A meta-analysis of changes in the stringency of psychiatric diagnosis from DSM-III to DSM-5. Clinical Psychology Review, 80.
Fineberg, N.A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B.M., Albert, U., Geller, D.A., Brakoulias, V., Reddy, Y.J., & Menchon, J. M. (2020). Clinical advances in obsessive-compulsive disorder: A position statement by the International College of Obsessive-Compulsive Spectrum Disorders. International Clinical Psychopharmacology, 35(4), 173-193.
Kashyap, H., & Abramovitch, A. (2021). Neuropsychological research in obsessive-compulsive disorder: Current status and future directions. Frontiers in Psychiatry, 12(72), 160-71.
Kayser, R. R. (2020). Pharmacotherapy for treatment-resistant obsessive-compulsive disorder. The Journal of Clinical Psychiatry, 81(5).
Linde, E. S., & Varga, T. V. (2022). Obsessive-compulsive disorder during the COVID-19 pandemic—a systematic review. Frontiers in Psychiatry, 13(8), 68-72.
Ljungbeck, B., Forss, K. S., Finnbogadóttir, H., & Carlson, E. (2021). Content in nurse practitioner education–A scoping review. Nurse education today, 98(10), 46-50.
Nezgovorova, V., Reid, J., Fineberg, N. A., & Hollander, E. (2022). Optimizing first line treatments for adults with OCD. Comprehensive Psychiatry, 115.
O’Brien, E. M., O’Donnell, C., Murphy, J., O’Brien, B., & Markey, K. (2021). Intercultural readiness of nursing students: An integrative review of evidence examining cultural competence educational interventions. Nurse Education in Practice, 50(10), 29-66.
Rasmussen, A. R., & Parnas, J. (2022). What is obsession? Differentiating obsessive-compulsive disorder and the schizophrenia spectrum. Schizophrenia Research, 243, 1-8.
Sharma, E., Sharma, L.P., Balachander, S., Lin, B., Manohar, H., Khanna, P., Lu, C., Garg, K., Thomas, T.L., Au, A.C.L. & Stewart, S. E. (2021). Comorbidities in obsessive-compulsive disorder across the lifespan: A systematic review and meta-analysis. Frontiers in Psychiatry, 12.
Singh, A., Anjankar, V. P., & Sapkale, B. (2023). Obsessive-Compulsive Disorder (OCD): A comprehensive review of diagnosis, comorbidities, and treatment approaches. Cureus, 15(11), 2-7.
Wilson, C., Gattuso, J. J., Hannan, A. J., & Renoir, T. (2023). Mechanisms of pathogenesis and environmental moderators in preclinical models of compulsive-like behaviors. Neurobiology of Disease, 185(10), 62-73.
Xu, J., Hao, Q., Tang, Y., & Wang, Q. (2021). Optimal dose of serotonin reuptake inhibitors for obsessive-compulsive disorder in adults: A systematic review and dose–response meta-analysis. Frontiers in Psychiatry, 12(1), 79-99.